Related Experiment Video
Updated: Jul 18, 2026
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
Phenformin-associated lactic acidosis: pathogenesis and treatment
Annals of Internal Medicine
|November 1, 1977
Summary
Insulin is the preferred treatment for phenformin-associated lactic acidosis, significantly reducing mortality compared to other methods. Sodium bicarbonate is recommended only for severe cases to avoid adverse effects.
Area of Science:
- Clinical Medicine
- Pharmacology
- Toxicology
Background:
- Phenformin, a hypoglycemic agent, has been associated with a significant number of lactic acidosis cases.
- Lactic acidosis is a serious complication requiring careful management.
Purpose of the Study:
- To evaluate the effectiveness of different treatments for phenformin-associated lactic acidosis.
- To determine the optimal therapeutic approach for this condition.
Main Methods:
- Analysis of 552 reported cases of lactic acidosis in patients taking phenformin.
- Comparison of mortality rates across different treatment groups: insulin, sodium bicarbonate, and dialysis.
Main Results:
- A mortality rate of 42% was observed in the overall group of patients with phenformin-associated lactic acidosis.
- Insulin treatment showed a considerably lower mortality rate of 15%.
- Sodium bicarbonate administration should be carefully considered, being beneficial for severe acidosis but potentially harmful if overused in mild cases. Dialysis did not demonstrate a significant improvement in survival rates (48% mortality).
Conclusions:
- Insulin emerges as the treatment of choice for phenformin-associated lactic acidosis.
- Judicious use of sodium bicarbonate is advised, reserving it for severe cases.
- Dialysis does not appear to improve outcomes for this condition.
Related Concept Videos
01:20Pathophysiology of Diabetes
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:22Diabetic Ketoacidosis ll: Pathophysiology
Diabetic ketoacidosis (DKA) is a metabolic emergency characterized by hyperglycemia, ketonemia, and metabolic acidosis. It results from severe insulin deficiency and an excess of counterregulatory hormones, leading to uncontrolled lipolysis, ketogenesis, and widespread electrolyte and fluid disturbances.Pathophysiology The central event in DKA is a profound loss of insulin action. Without insulin, glucose uptake in insulin-dependent tissues is impaired, while hepatic glucose production...